Etiology and impact of cytomegalovirus disease on solid organ transplant recipients

被引:0
|
作者
McDevitt, Lisa M.
机构
[1] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA
[2] Tufts Univ New England Med Ctr, Boston, MA USA
关键词
antivirals; cytomegalovirus ifections; immunosuppressive agents; transplantation;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The characteristics, etiology, natural history, and direct and indirect effects of CMV disease in solid organ transplant recipients are described. Summary. CMV is a common herpesvirus that may be present in the donor or recipient of a solid organ transplant. Even though it is rarely pathogenic in healthy patients, transplant recipients are at risk for CMV viremia and symptomatic disease due to their immune-suppressed status. In addition to symptoms directly attributed to active disease, CMV can have a variety of indirect effects. Indirect effects may include additional infectious complications, posttransplant lymphoproliferative disease, allograft rejection, allograft loss, or death. The three most prevalent risk factors for CMV infection are seronegativity in a recipient of an organ from a CMV-seropositive donor, the type of organ transplanted, and the degree of immune suppression. CMV prophylaxis is effective at preventing disease, but may result in a delayed onset where CMV disease occurs once the prophylaxis is stopped. Conclusion. Knowledge of risk factors for CMV infection and disease, the natural history in transplant recipients, and its direct and indirect effects will help clinicians make appropriate decisions regarding the use of preventive strategies.
引用
收藏
页码:S3 / S9
页数:7
相关论文
共 50 条
  • [31] PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW
    Ladhani, M.
    Hodson, E. M.
    Webster, A. C.
    Strippoli, G. F. M.
    Craig, J. C.
    NEPHROLOGY, 2012, 17 : 68 - 68
  • [32] Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
    Hodson, E. M.
    Jones, C. A.
    Strippoli, G. F. M.
    Webster, A. C.
    Craig, J. C.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (02):
  • [33] IMPACT OF CYTOMEGALOVIRUS-INFECTION ON ORGAN TRANSPLANT RECIPIENTS
    RUBIN, RH
    REVIEWS OF INFECTIOUS DISEASES, 1990, 12 : S754 - S766
  • [34] Prevention and treatment of cytomegalovirus disease in solid organ transplant recipients: The clinical and economic impact of evolving strategies - Introduction
    Pescovitz, MD
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (23) : S3 - S4
  • [35] Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
    Owers, Daniel S.
    Webster, Angela C.
    Strippoli, Giovanni F. M.
    Kable, Kathy
    Hodson, Elisabeth M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02):
  • [37] Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients
    Strippoli, GFM
    Hodson, EM
    Jones, C
    Craig, JC
    TRANSPLANTATION, 2006, 81 (02) : 139 - 145
  • [38] Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
    Strippoli, GF
    Hodson, EM
    Jones, CJ
    Craig, JC
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [39] Characteristics of Ganciclovir Resistant Cytomegalovirus in Solid Organ Transplant Recipients
    Zuberi, Muhammad
    Hamandi, Bassem
    Ingram, Sara
    Munyal, Dipika
    Yi, Teresa
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2007, 60 : 62 - 62
  • [40] Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities
    Eid, Albert J.
    Razonable, Raymund R.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2007, 12 (06) : 610 - 617